---
title: "Thymosin Alpha-1"
canonical_url: https://peptidelibrary.app/library/thymosin-alpha-1
description: "28-aa thymic peptide (thymalfasin). Approved in several countries (Zadaxin) for hepatitis B and as an immune adjuvant; not FDA-approved in the US."
updated: 2026-09-26
publisher: Peptide Library
notice: "Research and educational use only. Not medical advice."
---

# Thymosin Alpha-1

Thymosin Alpha-1 (also called Thymalfasin or Zadaxin) is a thymic peptide. Thymosin alpha-1 is a 28-amino-acid acetylated peptide cleaved from prothymosin alpha, originally isolated from thymic tissue.

28-aa thymic peptide (thymalfasin). Approved in several countries (Zadaxin) for hepatitis B and as an immune adjuvant; not FDA-approved in the US.

Also known as: Thymalfasin, Zadaxin, Tα1.

Categories: Experimental.

## Classification

- Type: Thymic peptide / approved outside US
- Mechanism class: Thymic Peptide
- Development stage: Research only
- Regulatory class: Research compound, not FDA-approved

## Mechanism

Thymosin alpha-1 is a 28-amino-acid acetylated peptide cleaved from prothymosin alpha, originally isolated from thymic tissue. It acts as an immune modulator rather than an immune stimulant: it signals through Toll-like receptors, principally TLR2 and TLR9, on dendritic cells and monocytes, promoting their maturation and shifting T-cell differentiation toward a Th1 profile with increased interferon gamma and interleukin-2. It also augments natural killer cell activity and restores T-cell counts in lymphopenic states. Notably it does not appear to drive inflammation in the way a direct cytokine would, which is why it has been studied both in infection and in sepsis. It is approved in several countries outside the United States.

Targets: T cells, Innate immune receptors.

Origin: Synthetic N-acetylated thymosin α1.

## Properties

- Sequence: Ac-Ser-Asp-Ala-Ala-Val-Asp-Thr-Ser-Ser-Glu-Ile-Thr-Thr-Lys-Asp-Leu-Lys-Glu-Lys-Lys-Glu-Val-Val-Glu-Glu-Ala-Glu-Asn-OH
- Molecular formula: C129H215N33O55
- Molecular weight: 3,108.3 g/mol
- CAS number: 62304-98-7
- Half-life: ~2 hours
- Studied routes: Subcutaneous

## Evidence

- Evidence level: Clinical Trial Evidence
- Highest documented: Controlled human trials
- Human trials: 2
- Controlled human trials: 2
- Preclinical sources: 0
- Latest source: 2023

Each step shows whether the sources Peptide Library has reviewed include that kind of research. Counts are reviewed sources, not every study ever published. Reviews and programme summaries that describe human use are shown as "reported", not as trials, and registered trials without published results are listed but not counted. A higher step means research has progressed further; it does not mean a compound works better or is safer. Compounds whose evidence has not been reviewed yet show "Not reviewed" instead of a guess.

### Studies

1. Immune enhancement in patients with predicted severe acute necrotising pancreatitis: a multicentre double-blind randomised controlled trial. Intensive Care Med. 2022. 2022. Controlled human trial. Population: Patients with predicted severe acute necrotising pancreatitis. Immune enhancement and infection [Source](https://pubmed.ncbi.nlm.nih.gov/35713670/)
2. A pilot trial of Thymalfasin (Ta1) to prevent COVID-19 infection and morbidities. Int Immunopharmacol. 2023. 2023. Controlled human trial. Population: Randomised participants (n=194). Infection and morbidity [Source](https://pubmed.ncbi.nlm.nih.gov/36881981/)
3. NCT02867267 — The Efficacy and Safety of Ta1 for Sepsis. Human study (early or uncontrolled). Population: Patients with sepsis (n=1106). Efficacy and safety in sepsis. Limitations: Registered trial with no published results yet. [Source](https://clinicaltrials.gov/study/NCT02867267)
4. NCT05086614 — Thymosin-alpha 1 for Adjuvant Treatment After Radical Resection of High-risk Hepatocellular Carcinoma. Human study (early or uncontrolled). Population: Patients after radical resection of high-risk hepatocellular carcinoma (n=2500). Recurrence-free survival. Limitations: Registered trial with no published results yet. [Source](https://clinicaltrials.gov/study/NCT05086614)

### Registered trials

- [NCT02867267](https://clinicaltrials.gov/study/NCT02867267)
- [NCT05086614](https://clinicaltrials.gov/study/NCT05086614)

## Safety

Side effects: Injection-site reactions; Flu-like symptoms.

Risks: Not FDA-approved.

Contraindications: Thymic tumors.

Human safety basis: Clinical trial reports

Key limitations: Not approved by the FDA for any use..

## Regulatory status

Thymosin Alpha-1 is not an FDA-approved product. It is sold for laboratory research and has no approved medical use.

- FDA status: Not Approved
- Availability: Research-Only

## Frequently asked questions

### What is Thymosin Alpha-1?

28-aa thymic peptide (thymalfasin). Approved in several countries (Zadaxin) for hepatitis B and as an immune adjuvant; not FDA-approved in the US. Thymosin alpha-1 is a 28-amino-acid acetylated peptide cleaved from prothymosin alpha, originally isolated from thymic tissue. It acts as an immune modulator rather than an immune stimulant: it signals through Toll-like receptors, principally TLR2 and TLR9, on dendritic cells and monocytes, promoting their maturation and shifting T-cell differentiation toward a Th1 profile with increased interferon gamma and interleukin-2.

### What are the side effects of Thymosin Alpha-1?

Side effects recorded for Thymosin Alpha-1 from clinical-trial reports include injection-site reactions and flu-like symptoms. Cautions recorded on this profile: thymic tumors. This is reference information, not medical advice.

### How does Thymosin Alpha-1 work?

Thymosin alpha-1 is a 28-amino-acid acetylated peptide cleaved from prothymosin alpha, originally isolated from thymic tissue. It acts as an immune modulator rather than an immune stimulant: it signals through Toll-like receptors, principally TLR2 and TLR9, on dendritic cells and monocytes, promoting their maturation and shifting T-cell differentiation toward a Th1 profile with increased interferon gamma and interleukin-2.

### Is Thymosin Alpha-1 FDA approved?

No. Thymosin Alpha-1 is not approved by the FDA for any indication and is categorised as research-only. It has not been reviewed for safety or efficacy as a medicine, and published research should be read as investigation rather than established use. FDA's compounding lists show 503A nomination: Previously in Category 2; nomination withdrawn by the nominators.

### What is the half-life of Thymosin Alpha-1?

Reported half-life for Thymosin Alpha-1 is ~2 hours. Half-life describes how long the compound persists in circulation, not how long any effect lasts, and published figures vary with route of administration, formulation and the population studied.

### What is the amino acid sequence of Thymosin Alpha-1?

Thymosin Alpha-1 has the sequence Ac-Ser-Asp-Ala-Ala-Val-Asp-Thr-Ser-Ser-Glu-Ile-Thr-Thr-Lys-Asp-Leu-Lys-Glu-Lys-Lys-Glu-Val-Val-Glu-Glu-Ala-Glu-Asn-OH, giving a chain of 30 amino acids. Its molecular formula is C129H215N33O55.

### What peptides are similar to Thymosin Alpha-1?

Compounds most often compared with Thymosin Alpha-1 include Thymalin, Thymogen (Oglufanide), Thymopentin and Thymulin. They are grouped by shared mechanism or research area rather than by equivalence, and their regulatory status and evidence base differ.

## References

- [Comprehensive Review of the Safety and Efficacy of Thymosin Alpha 1 in Human Clinical Trials — Altern Ther Health Med, 2024](https://pubmed.ncbi.nlm.nih.gov/38308608/)
- [Thymosin α-1 in Cancer Therapy: Immunomodulatory Mechanisms, Clinical Applications, and Translational Perspectives — Eur J Pharmacol, 2026](https://pubmed.ncbi.nlm.nih.gov/42641753/)
- [Aging and Thymosin Alpha-1 — Int J Mol Sci, 2025](https://pubmed.ncbi.nlm.nih.gov/41373628/)
- [Phenotypic drug discovery: a case for thymosin alpha-1 — Front Med (Lausanne), 2024](https://pubmed.ncbi.nlm.nih.gov/38903817/)
- [Thymosin alpha 1 treatment for patients with sepsis — Expert Opin Biol Ther, 2018](https://pubmed.ncbi.nlm.nih.gov/30063866/)

Note: Dose figures are left out of this Markdown version. See the cited sources.
